INTRODUCTION
Multiple sclerosis (MS) is being increasingly recognized as a complex neurodegenerative dis order of the brain and spinal cord that involves autoimmune mechanisms that target both white and gray matter elements. The disease is charac terized by demyelination, gliosis, axonal dysfunc tion, and, ultimately, neuronal loss. 1 The vast majority of individuals destined to have con firmed MS later in their lives will already exhibit disseminated plaque lesions, as revealed by conventional MRI techniques, at the time of their first inflammatory demyelinating event. 2 New and revised diagnostic criteria have enabled us to expedite the confirmation of MS, with substantial implications for early intervention with disease modifying treatment. [2] [3] [4] However, the ability to accurately image both neurodegeneration and its prevention in MS would greatly facilitate the systematic evaluation of novel therapeutics and their efficacy over time.
In MS, a dissociation is widely acknowledged to exist between the lesional burden seen on MRI scans and the corresponding clinical deficits documented on formal neurological examina tion, a phenomenon referred to as the 'clinico radiological paradox' . 5 Evidence has emerged that links early inflammation (e.g. clinical exacerbations and MRI lesions) with a likelihood of diseaserelated disability, and with the time scale of its evolution. For instance, we now recog nize that patients with high MRI lesion burdens at presentation represent a highrisk group for early and substantial disability. 6 While substan tial 'silent' disease activity is a classic feature of MS, the gradual accumulation of lesions will ulti mately lead to the disconnection of disparate and clinically relevant neural pathways.
The application to MS of nonconventional MRI techniques such as magnetization transfer imaging, magnetic resonance spectroscopy, and diffusion tensor imaging, has led to modest achievements in linking imaging data with clini cal measures of disease severity. 7 However, despite these improvements, until recently the progress in coupling specific clinical syndromes in MS with pathological changes within discrete tract systems was limited. [8] [9] [10] This Review describes a number of advancements in the application of optical coherence tomography (OCT), a tech nology that enables objective analysis of the processes of neurodegeneration within a highly discrete and eloquent CNS structure-the retina. OCT enables investigators to rapidly and repro ducibly evaluate the structural composition of the retina and to provide unique insights into this structure. While already validated for the longitudinal assessment of glaucoma 11, 12 and macular degeneration, 13 OCT is currently being investigated for its utility in tracking the progress of neurodegeneration in MS. Ultimately, OCT could substantially increase our understanding of the mechanisms of tissue injury in MS, could be used to identify new therapeutic strategies focused on neuroprotection of central axonal and neuronal structures, and could even enable the detection and monitoring of the processes of neurorestoration, a treatment goal not yet within the capability of the neurologist (but certainly a central goal in modern neurobiology).
BeNeFITS OF eARLY DIAGNOSIS AND TReATMeNT IN MS
The benefits of early treatment in MS are now widely accepted. Three studies based on class I evi dence have been published that have demonstrated clinical and radiographic benefits (at least in the short term) in individuals with MS who were treated at the time of the first exacerbation of their disease compared with those who were randomly allocated to receive placebo. [14] [15] [16] Furthermore, extensions of these studies suggested that the individuals in whom treatment was delayed for 2 years because of allocation to placebo accrued more disease activity and, when later treated, seemed to derive much less benefit, than did those who were treated at presentation. 17 During the transition from the inflammatory to the degenerative and progressive phases of MS, immunological mechanisms that underlie adap tive and innate immune dysregulation continue to operate, as they most probably do from the inception of the disease process. However, with an increasing burden of tissue injury over time, certain thresholds may be exceeded beyond which repair processes are ineffective. 18 Microglia mediated injury cascades, along with the amplifi cation of excitatory amino acid mechanisms, seem to figure prominently in the emerging predominance of innate immune mechanisms (particularly when such mechanisms are no longer acting in response to foreign antigens such as viruses or bacteria but instead are directed against selfepitopes, as in autoimmune dis eases). 19 The ability to generate or harness neuro protective mechanisms would usher in a new era of therapeutic neurobiology with implications for neurodegenerative disorders in general, and MS in particular.
THe eYe AS A MODeL OF NeURODeGeNeRATION
The retina is a unique CNS structure in that it contains axons and glia in the absence of myelin. The macula (which is about 1,200 µm in dia meter) is easily identified within the retina, where it produces its characteristic depression, with the center diameter of about 200 µm being occupied by the fovea and foveola. The foveal portion of the macula contains the highest density of cones, which contribute most to acuitybased and color visual processing. With the understanding that myelination in the visual pathway begins slightly behind the eye at the level of the lamina cribrosa, this unique structural specialization of the retina provides an opportunity to study the proximal effect on isolated axons of a disease process that most often occurs in the retrobulbar myelinated portion of the optic nerve.
Recent studies have demonstrated that optic neuritis seems to provide a useful clinical model with which to couple clinical measures of visual function with validated and objective structural and physiological correlates of MS. 20 The ante rior visual system is such a frequent target of the MS disease process that, on postmortem analysis, almost all patients with MS are found to have characteristic MS changes in the retina and optic nerve, regardless of whether they have previously experienced acute optic neuri tis (AON) 21, 22 -although as many as 30-70% of patients with MS will, in fact, have inflam matory optic neuritis during the course of their disease. 20, 23 When an individual has no history of the disorders that produce such characteristic findings (e.g. glaucoma and macular degenera tion), these findings are typically absent. These data suggest that the visual system has a very high predilection for developing diseaserelated disability both from acute episodes of AON and from the moreconstitutive elements of the disease process that contribute to an MSrelated chronic optic neuropathy, and that it could be fROhmaN et al. dEcEmbER 2008 vOL 4 NO 12 www.nature.com/clinicalpractice/neuro used effectively to illustrate the histopathology of the disease process in MS.
In contrast with occult optic neuropathy in MS, which is a largely subclinical manifesta tion of disease in the anterior visual system, most cases of AON are associated with pain and with visual disturbances, including diminished vision, color desaturation, poor lowcontrast acuity and sensitivity, and field abnormalities. 20 AON can, therefore, be evaluated with clini cal and neurophysiological techniques, such as patientreported acuity (high and low contrast) and sensitivity, visual field analysis, and visual evoked responses. 20, 23 Furthermore, coronal, fat suppressed, T1weighted gadoliniumenhanced MRI will reveal enhancement in the optic nerve in over 90% of cases of optic neuritis, con firming a breach in the integrity of endothelial tight junctions at the blood-brain barrier. 24 Studies with conventional MRI have shown that the optic nerve area declines subsequent to an event of AON in MS, when compared with the unaffected (or at least not acutely affected) eye. 25 Retinal imaging techniques have added greatly to our knowledge of this area, revealing further changes in retinal architecture that reflect altera tions in visual system physiology and function. For instance, the measurement of lowcontrast letter acuity has been validated as a useful and reproducible measure of visual function in patients with MS who present with acute optic neuritis but do not have a known history of this condition. 26, 27 Visual function has been shown to directly relate to the integrity of retinal anatomy, with abnormalities in this complex structure following optic neuritis producing corres ponding clinical deficits in patient performance on vision tests. 28 However, since visual function is a measure of both anterior and posterior visual pathways, and patientreported measures can be highly subjective and modified by a number of factors (e.g. fatigue, ambient and core body temperature, exercise, stress, and infection), novel imaging approaches that are specific to the retina and optic nerve may enable morespecific, more reliable, and morereproducible quantification of axon injury related to optic neuritis. 29 A direct bedside visualization of the retina and optic nerve was first achieved in 1851 following the introduction of the handheld ophthalmo scope by Helmholtz. 30 Over a century later, in 1974, Frisén and Hoyt reported for the first time a subjective analysis of thinning of the retinal nerve fiber layer (RNFL; which is principally composed of axons from ganglion cell neurons) in patients with MS, as evaluated with hand held ophthalmoscopy. 31 This observation was corroborated in 1994 in a postmortem study that demonstrated atrophy of the RNFL in 35 out of 49 eyes of patients with MS. 32 Nevertheless, this study was not sufficiently quantitative to enable a full appreciation of the relation ship between vision, RNFL thickness, and the integrity of the approximately 1.2 million axons that make up the optic nerve.
In recent years, we have observed the emer gence of 'quantitative ophthalmoscopes' such as Heidelberg Retinal Tomography (HRT), laser polarimetry with variable corneal compensation (GDxVCC), and OCT, all of which can be used to efficiently and objectively measure changes in structural architecture within the retina. 28, 33 THe PHYSICS OF OPTICAL COHeReNCe TOMOGRAPHY OCT was first reported by Huang et al. in 1991. 34 In vivo retinal imaging was first demonstrated in 1993, 35, 36 and early studies in 1995 provided the first demonstration of OCT imaging of the normal retina 37 and of macular pathology. 13 OCT is the optical analog of ultrasound Bmode imaging (Box 1). With OCT, highresolution crosssectional or threedimensional images of the internal retinal structure are generated by an optical beam being scanned across the retina and the magnitude and echo time delay of back scattered light being measured ( Figure 1 ). In contrast to ultrasonography, direct detection of light echoes is not possible with OCT, because the speed of light is much faster than the speed of sound; therefore, correlation techniques must be used. Early OCT systems were based on low coherence interferometry, a technique initially demonstrated by Sir Isaac Newton. With this technique, measurements are performed by use of a Michelsontype interferometer with a low coherencelength, superluminescent diode light source. One arm of the interferometer directs light onto the sample and collects the back scattered signal. A second reference arm has a reflecting mirror, which is mechanically con trolled to vary the time delay and measure inter ference. The use of a lowcoherencelength light source means that interference occurs only when the distance traveled by the light in the sample and reference arms of the interferometer match to within the coherence length. This characteristic enables measurement of the echo delays of the light from the tissue with extremely high tempo ral accuracy. The resulting data set is a two dimensional or threedimensional array, which represents the optical backscattering in a cross section or volume of the tissue. These data can be processed and displayed as a twodimensional or volumetric grayscale or falsecolor image (Box 1).
Since the inception of OCT, its performance has been improved by dramatic technological advances. 38 The development of 'Fourier domain' (or 'spectral domain') detection, a technique first proposed in 1995, has in particular enhanced ophthalmic OCT technology. Spectral domain OCT detects light echoes by measuring the inter ference spectrum of the infrared light by use of an interferometer with a stationary reference arm. A spectrometer and highspeed linescan camera record the interference spectrum, which is Fourier transformed to obtain the magnitude and echo time delay of the light (the axial scan). Spectral domain OCT detects all light echoes simultaneously, leading to a dramatic increase in sensitivity that enables highspeed imaging. [39] [40] [41] Retinal imaging with spectral domain OCT became possible only with recent advances in camera technology. The first retinal images with this technique were reported in 2002, 42 and highspeed, highresolution retinal imaging was demonstrated in 2003. 43, 44 The technology became commercially available in 2006; most commercial instruments achieve axial image resolution of 5-7 µm with imaging speeds of 25,000 axial scans per second, approximately 50 times faster than the previous generations of OCT technology. [39] [40] [41] [42] [43] [44] [45] 
APPLICATION OF OPTICAL COHeReNCe TOMOGRAPHY IN MS
The earliest application of OCT technology to the study of MS was reported by Parisi et al. in 1999. 46 In this study, which used firstgeneration OCT technology, 14 patients with MS who had com pletely recovered from a previous event of optic neuritis were compared with 14 agematched control individuals with respect to RNFL thick ness measures. The thickness of the RNFL was shown to be reduced by an average of 46% in the affected eyes of the patients with MS versus the eyes of controls (P <0.01), and by an average of 28% when affected eyes were compared with the 'unaffected' eyes of the same patient (P <0.01). Even in the supposedly unaffected eyes of the patients, however, there was an average 26% reduction in RNFL thickness when compared with control eyes (P <0.01).
In 2005, Trip and colleagues reported their observations with early generation OCT techno logy in 11 patients with MS and 14 patients with clinically isolated syndrome, all of which www.nature.com/clinicalpractice/neuro individuals had a history of a single episode of optic neuritis. 47 The study was a crosssectional analysis with followup ranging from 1 to 9 years after the optic neuritis event. Corroborating the previous findings of Parisi et al., the investi gators found an average 33% reduction in RNFL thickness in the affected eyes of patients when compared with the eyes of matched controls, and an average 27% reduction when the affected and unaffected eyes of the same patient were compared (P <0.001). Trip et al. extended the utility of OCT by also showing that the macular volume (a reflection of retinal ganglion cell neuronal integrity) was reduced by an average of 11% in the affected eyes of patients with a history of optic neuritis when compared with the eyes of control (P <0.001), and by 9% in the affected versus the unaffected eye of the same patient (P <0.001). An important finding of these studies was that the apparently unaffected eyes of patients with MS were in fact significantly abnormal when compared with the eyes of control indivi duals but were less abnormal than the eye with a history of AON. This finding indicates that AON signifies accelerated and moresevere histopathological consequences on the retina, in contrast to a more insidious and less perceptible change in individuals without a history of an acute syndrome, in whom the disease process probably more closely resembles glaucoma.
As a validation of the fact that RNFL thinning, as measured by OCT, is attributable to axonal degeneration, Trip and colleagues showed that www.nature.com/clinicalpractice/neuro such measures correlated better with visual evoked potential P100 amplitudes (a measure of axonal integrity or function) than with P100 latency (typically a reflection of myelin integ rity). 47 It is now generally accepted that disrup tion of myelin has a direct impact on the function and preservation of axons. 1 
Effective repair mechanisms would be expected to ultimately result in greater preservation of RNFL thickness as measured by OCT.
In 2006, Costello and colleagues reported that about 75% of patients with MS who have AON will sustain 10-40 µm of RNFL loss within a period of only about 3-6 months following the initial inflammatory event. 48 This finding is striking given that the RNFL is only about 110-120 µm thick by the age of 15 years, and that most individuals (without a history of glaucoma or macular degeneration) will lose only about 0.017% per year in retinal thick ness, which equates to approximately 10-20 µm over 60 years. 49 Costello et al. also provided compelling evidence to identify an injury thres hold within the RNFL of about 75 µm; thinning of the RNFL below this level led to a corres ponding decay in visual function, as measured by automated perimetry. This finding suggests that visual function seems to be preserved until a certain level of retinal axonal loss has been reached.
The development of validated measures of visual functioning has greatly facilitated the exploration for a structural biomarker for neuro degeneration in MS. Balcer's group has used performance on lowcontrast letter acuity charts to compare retinal structure imaged with early (third) generation OCT technology (OCT 3 with 4.0 software) with visual function in patients with MS who have MS pathology in the anterior visual system. 50 In this study, patients with MS and a history of optic neuritis were shown to have lower thickness measures of the RNFL than patients with MS but no history of optic neuritis, as well as lower thickness measures than individuals without a history of either condition. The fact that severity of visual loss (as confirmed by performance on automated perimetry or low contrast letter acuity) is a predictor of abnor mal retinal architecture is further evidence that OCT could be used as a noninvasive approach to monitor the course of disease in patients with MS and that the technique could be used to detect and monitor the efficacy of new therapies targeting mechanisms that might promote neuro protective effects on retinal axons and ganglion cell neurons (Figures 2-5 ; Box 1). Axonal and neuronal degeneration might be readily expected to be present in eyes with a known history of AON. In the Balcer investi gation that used OCT, RNFL thickness was examined in heterogeneous MS cohorts, and the researchers assessed whether scores for low contrast letter acuity might also reflect RNFL thinning in the eyes of patients with MS who do not have a history of AON. 50 Among 90 patients with MS (180 eyes) and 36 control individuals without MS (72 eyes), the average RNFL thickness was significantly reduced in the former group (including patients with and those without a history of AON). As expected, eyes of patients with MS who had a known history of one or more attacks of AON had significantly lower RNFL thickness (mean 85 ± 17 µm) than did the eyes of patients with MS who did not have an AON history (mean 96 ± 14 µm; P <0.001). RNFL thickness was also reduced in the eyes of patients with MS without an AON history compared with the eyes of control individuals (mean 105 µm; P = 0.03). By use of normative data included in the 4.0 software for the Stratus OCT3 TM (Carl Zeiss Meditec, Inc), only 40 (22%) of 180 eyes from patients with MS were determined to have 'abnormal' average RNFL thickness. 50 In view of the fact that the OCT 4.0 normative database (which is based on a large normal population cohort characterized for age and sex by the manufacturer) considers the fifth percentile for age to be the cutoff for abnormal values, however, abnormalities in RNFL thickness are likely to be of substantially greater prevalence in the eyes of patients with MS and optic neuritis.
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Results from the Balcer study also suggest that the 'unaffected' eyes of patients with MS who have a history of AON are at a similar risk for axonal loss to the eyes of patients with MS in general; both MS groups have more axonal loss than do agematched control individuals. The investigators also found that lowcontrast letter acuity scores were significantly correlated with overall average RNFL thickness in the eyes of patients with MS (P <0.001 by use of generalized estimating equation models accounting for age and adjusting for withinpatient, inter eye correlations); for every oneline change in lowcontrast letter acuity score, an average RNFL thickness difference of 4 µm was noted. Average overall RNFL thickness also declined with increasing degrees of overall neurological impairment and disability in the MS cohort, and the thickness was significantly associated with Expanded Disability Status Scale (EDSS) score and disease duration (P = 0.02 for linear trend across EDSS tertiles 0.0-1.5, 2.0-2.5, and 3.0-7.0).
The severity of RNFL thinning as measured by OCT has now been shown to be predicted through the segregation of MS into its various subtypes (Box 1). 51, 52 In particular, patients with a more progressive disease course are found to have moresubstantial retinal pathology, as measured by RNFL loss. With increasing brain atrophy, as measured by validated metrics (such as the brain parenchymal fraction), there is a corresponding reduction in RNFL thickness. 53, 54 Thus, the eye would seem to be capable of accu rately modeling the mechanisms of neuro degeneration and could even be used to monitor neuroprotection in MS. Specifically, with OCT we can measure the integrity of both neurons and their axonal projections within the retina; the severity of retinal damage directly correlates with clinical visual dysfunction, and with both ncpneuro-2007-254f3.eps Figure 3 An optical coherence tomography (OCT) report for the macular region of the retina from the same patient with multiple sclerosis as is shown in Figure 2 . Note the volume reductions in the foveola (central macula) and the parafoveal quadrants on the left of the report. Whereas the reductions in retinal nerve fiber layer thickness implicate loss of ganglion cell axons, macular changes implicate losses of the ganglion cell neurons themselves. While the patient has had no history of optic neuritis in the right eye, there are some subtle macular changes on that side, suggesting occult involvement of this eye as well. Abbreviations: OD, right eye; OS, left eye.
the severity of MSrelated brain pathology (i.e. atrophy) and MS clinical subtype designations (as stratified by disease progression status; Box 1).
THe FUTURe OF ReTINAL IMAGING IN MS
The hypothesis that measures of the RNFL are causally related to visual performance has been corroborated in recent experiments by our group with another type of quantitative ophthalmo scope, GDxVCC (Box 1). GDxVCC is based on the projection of polarized light into a tissue (such as the retina) and the measurement of polarization retardation when the light is propa gating through a birefringent medium (such as the RNFL). Water is not a birefringent medium and thereby produces no light retardation; as such, edema does not affect GDx measurements. GDxVCC can be used to generate thickness measures of the RNFL that are analogous and related to measures derived from OCT. The principal structure within the RNFL that serves to retard light is the axonal microtubules; this technology's method is, therefore, distinctly different from that of OCT, which measures RNFL thickness taking into account axons, glia, and tissue water. One of the strengths of GDx is that it would seem to denote the quantita tive distribution of the nerve fiber regardless of thickness due to edema. 55 Notwithstanding the differences between imag ing technologies, we have confirmed that OCT and GDx metrics yield very similar findings with respect to visual loss in patients with MS who have optic neuritis (Figures 4,5) . 56 Like OCT, GDxVCC produces measures that correlate with performance on lowcontrast letter acuity charts and with changes in visual field; however, GDx can additionally detect abnormalities even www.nature.com/clinicalpractice/neuro when they are highly restricted to a particular distribution (Figures 4,5) . OCT is also, however, undergoing improve ments. The high imageacquisition speeds afforded by the spectral domain instruments enable the generation of highdefinition OCT images with increased numbers of transverse pixels and improved coverage of the retina, as well as the acquisition of threedimensional OCT (3DOCT) data sets. 3DOCT imaging is especially promising, because projection image data can be summed to provide a virtual fundus image, which enables precise and reproducible registration of individual OCT images to fundus features. 57, 58 Together, these features promise to improve the reproducibility of RNFL thickness measurements and other morphometric measure ments. Furthermore, 3DOCT data can be pro cessed to generate virtual circumpapillary scans, which can be coregistered to retinal features during post processing ( Figure 6 ). Volumetric 3DOCT data also provide comprehensive information about the optic disc. RNFL thickness maps (analogous to retardance maps from the GDx), or topographic maps (similar to those from HRT), can be generated for greater retinal depth (threedimensional) analysis. 58 Some important issues remain to be addressed. Different OCT instruments have different measure ment protocols as well as different data analysis methods, so careful quantitative studies must be performed to compare morphometry results and to establish consistent normative baselines. In addition, questions remain about which proto cols or visualization methods are best suited for a given application, depending upon the disease process and the resultant impact upon axons, neurons, or both. The new OCT devices offer automated disc centering, longitudinal co registration to minimize scantoscan variability, and correction for eye movements that have pre viously resulted in retinal slip and image quality degradation. These advantages substantially improve the accuracy attained by the examin ing technician in comparison with earlier OCT technologies for which manual methods of scan alignment is required (a source of scantoscan variability). The improved visualization and per formance of new OCT technology suggests that this technique will have an increasingly impor tant role in the assessment of processes of axonal and neuronal degeneration in neurological disease in general, and MS in particular.
CONCLUSIONS
A major advance in modern neurobiology has been the development of the ability to couple highly stereotyped clinical syndromes with predictable histopathological signatures in dis crete neuroanatomical tract systems. We believe that retinal imaging is vital to link these processes in MS. While a clinical outcome of vision testing would at first glance seem to be sufficient to couple pathological mechanisms of MS with relevant outcome measures in clinical trials that test new treatment strategies, our ultimate objec tive is to determine whether what we observe in the eye is translatable to what we would see in the brain and spinal cord in general (Box 2). The relationship between these anatomical compartments is complex in that the struc tural composition of the disease process may be similar in both locations, and the potential clinical metrics to be validated for confirming protective or even restorative effects are mani fold. As such, we require a structure-function paradigm when designing novel trials, to which the integration of OCT or similar technology is essential. An additional advantage of using these ncpneuro-2007-254f5.eps new technologies for the corroboration of neuro protective effects is that they give serial structural measures over time that are highly reliable, not affected by physiological factors (e.g. temperature, infection, stress or exercise) and have a very low intertest variability. 59 By contrast, serial measures of any clinical outcome can be highly variable across time, particularly in a disorder such as MS in which a high degree of reversible conduction slowing (or even block) is well recognized (the socalled 'Uhthoff phenomenon'). Initially employed as a secondary outcome measure in clinical trials of MS, but now with sufficient prospective validation, OCT rep resents a new primary outcome measure as it directly correlates with a clinically meaningful outcome-contrast letter acuity-for patients. The modeling of processes such as neuro degeneration and neuroprotection in MS will, however, require enormous precision and repro ducibility if we are to confirm our assumptions about how the pathology evolves and whether therapeutic intervention to change these pro cesses is feasible. Prospective studies will be required to demonstrate predictive validity of these techniques and the disease specificity of models such as optic neuritis. Specifically, does this window on the brain work only for MS, or are there similar changes in other neuro logical diseases? A recent report, for example, showed that the RNFL is abnormal in Alzheimer disease, 60 and this point requires further investi gation to ensure that the RNFL findings in MS are being correctly interpreted.
Ultimately, retinal imaging technologies such as OCT could be used to rapidly evaluate the integrity of the RNFL and the macula for the purpose of tracking disease progression in MS, and could also potentially be used to visualize neuroprotection. Importantly, studies have demonstrated that thinning of the RNFL (through average RNFL, quadrant, and clockface sector analyses) and volume reductions in the macula are associated with stereotypic declines in visual functioning, particularly as measured by lowcontrast letter acuity and visual field analyses (Box 1). [46] [47] [48] 50, 51, 53 Using the eye as a model for the brain would facilitate an efficient, costeffective strategy by which we could longitu dinally follow changes in structure along with their clinical concomitants, and thereby refine our characterization of the disease process in MS and develop the capability to monitor therapeutic effects to alter disease progression. 
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